• Study will begin soon

Evaluation of supervised consumption services (SCS) in the context of COVID-19 through the development of an evidence-based model simulating the rate of overdose among people who attended SCS in Montreal.


The ongoing COVID-19 crisis is a major social disruption, and fatal overdoses have increased during the pandemic in a variety of settings, including Canada. people who inject drugs are particularly vulnerable to the impact of major disruptive events.

The present study will use pre-existing data from  Supervised consumption services and other provincial sources to reduce the acute harms associated with injection drug use. For example, harms related to overdose, disease transmission, and bacterial infection will be reduced by providing services including emergency medical care, harm reduction supplies, and other support responsive to the needs of people who inject drugs.


This study aims to:

  •  Examine changes that have occurred since the COVID-19 pandemic within supervised consumption services, both at the system level and for SCS attendees
  • Model the impact of these changes on future overdose rates in the population, and project the potential to avert these by improving retention and engagement within SCS in the future

Principal Investigator

Co-investigators and Collaborators

  • Julie Bruneau, MD, MSc (Université de Montréal, CRCHUM)
  • Natasha Martin, PhD (University of California, San Diego)
  • Elaine Hyshka, PhD (University of Alberta)
  • Pascale Leclerc, MSc (Université de Montréal)
  • Thomas Brothers, PhD (Université Dalhousie)
  • Jean-François Mary, MSc (CACTUS Montreal)
  • Carole Morissette, MD (Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l’Île-de-Montréal)


  • Ruby Sniderman, MPH (CRCHUM)


CIHR's leaf identifier - full-colour

For more information on this evaluation study, please contact Ruby Sniderman at ruby.sniderman.chum@ssss.gouv.qc.ca

Start typing and press Enter to search